DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DexCom insider sale under pre-established plan; small number of shares sold. Michael Jon Brown, EVP and Chief Legal Officer of DexCom (DXCM), sold 500 shares of common stock on 08/15/2025 at a reported price of $80.29 per share. The sale was executed pursuant to a 10b5-1 trading plan adopted on 02/21/2025, which the filing states allows for orderly dispositions of his shares.
After the reported sale Mr. Brown beneficially owned 94,102 shares. The filing discloses that 86,490 of those shares are unvested restricted stock units, detailed by grant dates and vesting schedules (grants from 2022–2025 with vesting through March 8, 2028). The form is signed by an attorney-in-fact on 08/18/2025.
Mark G. Foletta, a trustee and director of DexCom, Inc. (DXCM), reported sales of company stock executed on 08/15/2025 under a pre-existing 10b5-1 plan. The filing shows two sale transactions: 2,555 shares sold at a weighted average price of $81.0186 (individual trade prices ranged $80.29–$81.22) and 195 shares sold at $81.54. After these transactions, the filing reports beneficial holdings by The Foletta Family Trust of 51,316 and 51,121 shares respectively. The report also discloses 5,731 unvested restricted stock units granted on May 8, 2025 that will vest on the earlier of the one-year anniversary of the grant or DexCom’s 2026 annual meeting.
Form 144 notice for proposed sale of securities under Rule 144. The filing shows an intended sale of 500 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $40,145, slated for 08/15/2025 on NASDAQ. The shares were acquired as restricted stock on 03/08/2024 from the issuer and paid in full on that date. The filing also reports three sales by the same person in the past three months totaling 11,000 shares for gross proceeds of $920,264. The filing identifies the seller in prior sales as Michael Brown.
DexCom (DXCM) Form 144 notice reports a proposed sale of 2,750 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $220,797.50 and approximately 392,155,265 shares outstanding. The shares were acquired as vested RSUs on 05/19/2022 and payment was recorded the same day. The filer notes an approximate sale date of 08/15/2025. The filing also discloses two prior sales by the same account: 2,750 shares on 06/16/2025 for $228,604.75 and 2,750 shares on 07/15/2025 for $234,216.67. The notice includes standard Rule 144 representations but contains no entered dates or signature data in the remarks section.